Redeye comments on the Q4 report from Bioservo. In total, a report without any surprises in our view...
Redeye saw slightly slower development than expected in Q4.
Redeye comments on Imint's Q4 report, which showed all-time net revenues and stable profitability.
Redeye’s preliminary revisions suggest minor adjustments to Hoylu’s “2022E and 2023E, as the Q4’21 w...
Vaisala’s Q4 topline was in line with our expectations, but earnings fell short due to declined marg...
Eltel’s profitability continues to improve, but we find valuation still doesn’t leave that much upsi...
Innofactor’s Q4 fell well short of our expectations as the company saw challenges relating to organi...
Pihlajalinna’s Q4 revenue grew as expected but profitability fell short of estimates due to the incr...
Redeye comments on Zordix announcement that is Christina Seelye Appointed as New CEO.
Redeye finds that Westpay’s report was better than we expected in terms of revenue; however, the pro...
Ferroamp redovisar ett svalt fjärde kvartal präglat av global komponentsbrist och leveransstopp hos ...
Redeye concludes that Q4 was in line with the high expectations.
Analysguiden inleder bevakning av e-handelsbolaget Purefun Group.
Redeye is growing more confident in the case, following a Q4 report with robust earnings and cash fl...
Redeye comments on Nanexa's Q4 report and summarize our view of progress in 2021.
SDS publicerade idag den 17 februari 2022 sin delårsrapport för fjärde kvartalet 2021.
Redeye comments on Scandion’s fourth quarter report for 2021, going into an important year for the c...
Redeye provides a comment on Amniotics’ Q4 report.
Redeye returns with a more in-depth take on BONESUPPORT’s Q4-report following the conference call an...
Redeye comments on aXichem’s Q4’21 report. The last quarter of 2021 included some interesting events...
